If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Publisher: Wiley-Blackwell

Related content
Volume 13, Supplement 2, November 2003

< previous issue | all issues | next issue >

Favourites:Add to Favourites

Proteomic analysis for early detection of ovarian cancer: A realistic approach?
pp. 133-139(7)
Authors: Stevens, E. V.; Liotta, L. A.; Kohn, E. C.

Favourites:Add to Favourites

What have we learned from ICON1 and ACTION?
pp. 140-143(4)
Authors: Colombo, N.; Pecorelli, S.

Favourites:Add to Favourites

Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer
pp. 144-148(5)
Authors: Piccart, M. J.; Bertelsen, K.; Stuart, G.; Cassidy, J.; Mangioni, C.; Simonsen, E.; James, K.; Kaye, S.; Vergote, I.; Blom, R.; Grimshaw, R.; Atkinson, R.; Swenerton, K.; Trope, C.; Nardi, M.; Kaern, J.; Tumolo, S.; Timmers, P.; Roy, J.-A.; Lhoas, F.; Lidvall, B.; Bacon, M.; Birt, A.; Andersen, J.; Zee, B.; Paul, J.; Pecorelli, S.; Baron, B.; Mcguire, W.

Favourites:Add to Favourites
Favourites:Add to Favourites

Improving first-line therapy of advanced ovarian cancer – the AGO Ovarian Cancer Study Group perspective
pp. 169-171(3)
Authors: Du Bois, A.; Pfisterer, J.; Meier, W.; Wagner, U.

Favourites:Add to Favourites

First-line treatment of ovarian cancer FIGO stages IIb–IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin
pp. 172-177(6)
Authors: Kristensen, G. B.; Vergote, I.; Stuart, G.; Del Campo, J. M.; Kaern, J.; Lopez, A. B.; Eisenhauer, E.; Aavall-Lundquist, E.; Ridderheim, M.; Havsteen, H.; Mirza, M. R.; Scheistroen, M.; Vrdoljak, E.

Favourites:Add to Favourites
Favourites:Add to Favourites

Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy
pp. 196-203(8)
Authors: Piccart, M. J.; Floquet, A.; Scarfone, G.; Willemse, P. H. B.; Emerich, J.; Vergote, I.; Giurgea, L.; Coens, C.; Awada, A.; Vermorken, J. B.

Favourites:Add to Favourites
Favourites:Add to Favourites

Consolidation therapies revisited: weekly paclitaxel
pp. 208-211(4)
Authors: Pecorelli, S.; Odicino, F.; Favalli, G.

Favourites:Add to Favourites

Cost-effectiveness studies in ovarian cancer
pp. 212-219(8)
Authors: Szucs, T. D.; Wyss, P.; Dedes, K. J.

Favourites:Add to Favourites

Translational research in ovarian cancer: a must
pp. 220-230(11)
Authors: Hamilton, T. C.; Connolly, D. C.; Nikitin, A. Y.; Garson, K.; Vanderhyden, B. C.

Favourites:Add to Favourites

Systemic treatment policies in ovarian cancer: the next 10 years
pp. 231-240(10)
Authors: Biagi, J. J.; Eisenhauer, E. A.

Favourites:Add to Favourites

Ovarian cancer treatment: what is new
pp. 241-250(10)
Author: Poveda, A.

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more